share_log

華領醫藥-B：建議採納第三份經修訂及經重述的組織章程大綱及細則

HUA MEDICINE-B: PROPOSED ADOPTION OF THE THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

香港交易所 ·  Apr 3 04:32
Summary by Moomoo AI
華領醫藥-B（股份代號：2552）董事會提出建議，將修訂公司的組織章程大綱及細則，以符合2023年12月31日生效的香港聯合交易所有限公司證券上市規則的最新修訂，該修訂主要涉及公司通訊的電子發佈方式。該修訂細則的採納需經股東於年度股東大會上以特別決議案形式批准。若股東批准，修訂細則將隨即生效。股東將收到包含修訂細則詳情的通函，以及股東年度大會的通知。該公告由行政總裁兼執行董事陳力博士於2024年4月3日發出。
華領醫藥-B（股份代號：2552）董事會提出建議，將修訂公司的組織章程大綱及細則，以符合2023年12月31日生效的香港聯合交易所有限公司證券上市規則的最新修訂，該修訂主要涉及公司通訊的電子發佈方式。該修訂細則的採納需經股東於年度股東大會上以特別決議案形式批准。若股東批准，修訂細則將隨即生效。股東將收到包含修訂細則詳情的通函，以及股東年度大會的通知。該公告由行政總裁兼執行董事陳力博士於2024年4月3日發出。
The Board of Directors of Hualien Pharmaceutical-B (Stock Code: 2552) has proposed to amend the Company's Articles of Association and Conditions to comply with the latest amendments to the Listing Rules of the Hong Kong United Stock Exchange Limited, effective December 31, 2023, which mainly concern the manner of electronic publication of the Company's communications. The adoption of these amended terms is subject to approval by shareholders in the form of a special resolution at the Annual General Meeting. If approved by shareholders, the revised terms will take effect immediately. Shareholders will receive a circular containing details of the revised terms and notice of the Annual General Meeting. The announcement was made by Dr. Chen Li, Chief Executive Officer and Executive Director, on 3 April 2024.
The Board of Directors of Hualien Pharmaceutical-B (Stock Code: 2552) has proposed to amend the Company's Articles of Association and Conditions to comply with the latest amendments to the Listing Rules of the Hong Kong United Stock Exchange Limited, effective December 31, 2023, which mainly concern the manner of electronic publication of the Company's communications. The adoption of these amended terms is subject to approval by shareholders in the form of a special resolution at the Annual General Meeting. If approved by shareholders, the revised terms will take effect immediately. Shareholders will receive a circular containing details of the revised terms and notice of the Annual General Meeting. The announcement was made by Dr. Chen Li, Chief Executive Officer and Executive Director, on 3 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more